Link to article at PubMed

2021 Feb 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.


Carvedilol is a non-selective adrenergic blocker indicated for the chronic therapy of heart failure with reduced ejection fraction (HFrEF), hypertension, and left ventricular dysfunction following myocardial infarction (MI) in clinically stable patients. Off-label indications for carvedilol include stable angina, atrial fibrillation, and cirrhotic esophageal variceal bleeding prophylaxis, and ventricular arrhythmias. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of carvedilol, pertinent for clinicians and other members of the interprofessional team to allow for appropriate utilization of carvedilol for indicated conditions.

PMID:30521289 | Bookshelf:NBK534868

Leave a Reply

Your email address will not be published.